Get started
Author

Shahzad Raza

Observed names: Raza, Raza Shahzad, Raza, Shahzad, S Raza, S. Raza, SHAHZAD RAZA, Shehzad Raza
Observed institutions: University of Vermont, Aga Khan University, Cleveland Clinic, Johnson & Johnson (United States), Mayo Clinic, Saint Luke's Health System, Columbia University Irving Medical Center, John H. Stroger, Jr. Hospital of Cook County, University of Missouri Health System, Military Hospital, Brookdale University Hospital and Medical Center, Aga Khan University Hospital, Cleveland Clinic Lerner College of Medicine, NYU Langone Health, Zymeworks (Canada), Mayo Clinic Hospital, Saint Luke's Hospital, Daiichi Sankyo (United States), Herbert Irving Comprehensive Cancer Center, Replimune Group, Inc. (United States), New York University, Case Western Reserve University, University of Missouri–Kansas City, University of Missouri, Columbia University
ORCID: 0000-0002-2739-2265
Observed ORCID: 0000-0002-2739-2265
OpenAlex ID: A5032260744
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
2019 · Maria-Victoria Mateos, Hilary Blacklock, et al. · The Lancet Haematology · 258
PDF
Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival
2008 · Ashwatha Narayana, Patrick Kelly, et al. · Journal of neurosurgery · 243
Insight into Sweet’s syndrome and associated-malignancy: A review of the current literature
2013 · SHAHZAD RAZA, ROBERT S. KIRKLAND, et al. · International Journal of Oncology · 116
PDF
A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma
2011 · Ashwatha Narayana, Deborah Gruber, et al. · Journal of neurosurgery · 116
Comparative proteogenomic analysis of right-sided colon cancer, left-sided colon cancer and rectal cancer reveals distinct mutational profiles
2018 · Robin Imperial, Zaheer Ahmed, et al. · Molecular Cancer · 113
PDF
The Pakistan Risk of Myocardial Infarction Study: a resource for the study of genetic, lifestyle and other determinants of myocardial infarction in South Asia
2009 · Danish Saleheen, Moazzam Zaidi, et al. · European Journal of Epidemiology · 107
PDF
Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial
2023 · Jong Wook Lee, Jong Wook Lee, et al. · The Lancet Haematology · 94
Feasibility of Using Bevacizumab With Radiation Therapy and Temozolomide in Newly Diagnosed High-Grade Glioma
2008 · Ashwatha Narayana, John G. Golfinos, et al. · International Journal of Radiation Oncology*Biology*Physics · 90
Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience
2023 · Danai Dima, James A. Davis, et al. · Transplantation and Cellular Therapy · 86
Bevacizumab in recurrent high-grade pediatric gliomas
2010 · A. Narayana, S. Kunnakkat, et al. · Neuro-Oncology · 83
PDF
High-grade glioma before and after treatment with radiation and Avastin: Initial observations
2008 · Ingeborg Fischer, Clare H. Cunliffe, et al. · Neuro-Oncology · 79
Immunomodulatory Drugs (IMiDs) in Multiple Myeloma
2017 · Shahzad Raza, Rachael A. Safyan, et al. · Current Cancer Drug Targets · 78
Interim analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis
2017 · Camille V. Edwards, Julia Gould, et al. · Amyloid · 68
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
2025 · Doris K. Hansen, Lauren C. Peres, et al. · Journal of Clinical Oncology · 54
Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management
2023 · Mariam Markouli, Fauzia Ullah, et al. · Current Oncology · 54
PDF
Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy
2024 · Danai Dima, Al-Ola Abdallah, et al. · Blood Cancer Journal · 53
Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab
2025 · Shaji Kumar, María-Victoria Mateos, et al. · New England Journal of Medicine · 48
Prone Hypofractionated Whole-Breast Radiotherapy Without a Boost to the Tumor Bed: Comparable Toxicity of IMRT Versus a 3D Conformal Technique
2011 · Matthew E. Hardee, Shahzad Raza, et al. · International Journal of Radiation Oncology*Biology*Physics · 48
Impact of Frailty on Outcomes after Chimeric Antigen Receptor T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma
2023 · James A. Davis, Danai Dima, et al. · Transplantation and Cellular Therapy · 47
Systemic AL amyloidosis: current approach and future direction
2023 · Maroun Bou Zerdan, Lewis Nasr, et al. · Oncotarget · 47
PDF
Timing of Toxicities and Non-Relapse Mortality Following CAR T Therapy in Myeloma
2024 · William Wesson, Danai Dima, et al. · Transplantation and Cellular Therapy · 41
Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy
2025 · Binod Dhakal, Othman S. Akhtar, et al. · Blood · 39
A Prospective Study on Red Blood Cell Transfusion Related Hyperkalemia in Critically Ill Patients
2015 · Shahzad Raza, Mahadi Ali Baig, et al. · Journal of Clinical Medicine Research · 39
PDF
The Evolution of Clostridium difficile Infection in Cancer Patients: Epidemiology, Pathophysiology, and Guidelines for Prevention and Management
2012 · Areej Khan, Shahzad Raza, et al. · Recent Patents on Anti-Infective Drug Discovery · 39
Clostridium Difficile Infection Following Chemotherapy
2009 · Shahzad Raza, Mahadi Baig, et al. · Recent Patents on Anti-Infective Drug Discovery · 37
Works count: 361
Citation count: 3,275
H-index: 29
I10-index: 71
Year
Topic
Type